How to Prescribe Symbicort
Symbicort (budesonide/formoterol) should be prescribed as twice-daily maintenance therapy at doses of 80/4.5 mcg (2 inhalations) or 160/4.5 mcg (2 inhalations) depending on disease severity, and should NEVER be used as monotherapy with the LABA component alone.
For Asthma
Patient Selection
Prescribe Symbicort for patients ≥12 years with moderate to severe persistent asthma (Step 3 care or higher) whose asthma is not adequately controlled on inhaled corticosteroids alone 1.
Dosing Algorithm
Step 3 (Moderate Persistent Asthma):
- Start with Symbicort 80/4.5 mcg, 2 inhalations twice daily (total daily dose: 320/18 mcg)
- This is the preferred combination therapy over increasing ICS dose alone 2, 3
Step 4-5 (Severe Persistent Asthma):
- Use Symbicort 160/4.5 mcg, 2 inhalations twice daily (total daily dose: 640/36 mcg)
- For patients requiring higher doses or with frequent exacerbations 1
Critical Safety Points
- LABAs must ALWAYS be combined with ICS - never prescribe formoterol alone for asthma maintenance 1, 3
- The FDA has issued warnings about LABA monotherapy increasing severe exacerbations and deaths 3
- Patients should use a separate short-acting beta-agonist (albuterol) for acute symptom relief, NOT additional Symbicort doses (in the US formulation) 1
Device Priming
Prime before first use by releasing 2 test sprays into the air, shaking well for 5 seconds before each spray. Re-prime if not used for >7 days or if dropped 4.
For COPD
Patient Selection
Prescribe Symbicort for patients ≥40 years with moderate to very severe COPD (FEV1 <50% predicted) who have:
- History of ≥2 exacerbations per year, OR
- Significant symptoms despite long-acting bronchodilator therapy 5, 6
Dosing
Standard COPD Dose:
This is the only FDA-approved strength for COPD maintenance.
When to Choose Symbicort Over Alternatives
Prefer ICS/LABA combination (like Symbicort) when:
- Patient has ≥2 exacerbations per year despite bronchodilator therapy 5
- Patient has features suggesting asthma-COPD overlap (bronchodilator reversibility, blood eosinophils ≥300 cells/mm³) 8
Consider alternatives when:
- Patient has <2 exacerbations per year: use LAMA monotherapy (tiotropium) or LAMA/LABA combination instead 9, 5
- Patient has recurrent pneumonia: ICS increases pneumonia risk by ~4% 5
Comparative Effectiveness
Symbicort reduces COPD exacerbations by 24% compared to formoterol alone (rate ratio 0.76) 7. It performs similarly to fluticasone/salmeterol for exacerbation prevention but may offer faster morning symptom relief due to formoterol's rapid onset 10, 11.
Common Prescribing Pitfalls
Never prescribe the LABA component alone - this is the most critical error and increases mortality risk in asthma 1, 3
Don't use ICS monotherapy in COPD - if prescribing ICS for COPD, it must be combined with a LABA 5, 6
Don't confuse US and European formulations - the SMART (maintenance and reliever therapy) regimen approved in Europe is NOT approved in the US 4, 12, 13
Monitor growth in children - though approved for ≥12 years, ICS can reduce growth velocity by ~1 cm/year 4
Adjust expectations for pneumonia risk - counsel COPD patients about 4% increased pneumonia risk with ICS/LABA combinations 5
Monitoring and Titration
- Titrate to the lowest effective dose that maintains control 4
- If using Symbicort 160/4.5 mcg twice daily and patient achieves good control for ≥3 months, consider step-down to 80/4.5 mcg twice daily
- If patient requires rescue inhaler >2 days/week (excluding pre-exercise use), this indicates inadequate control - increase therapy 1
- Monitor for oral candidiasis, dysphonia, and systemic corticosteroid effects 4
Special Populations
Hepatic impairment: Monitor closely as both budesonide and formoterol are hepatically metabolized; accumulation may occur 4
Geriatric patients (≥65 years): No dose adjustment needed, but use caution with cardiovascular comorbidities due to beta-agonist effects 4
Pregnancy: Weigh benefits against risks; uncontrolled asthma poses greater fetal risk than ICS therapy 4